CME Presentations




  • John Strickler, MD

    John Strickler, MD

    John Strickler, MD

    Associate Professor

    John Strickler, MD, is an Associate Professor at Duke University, where he is the Associate Director of Clinical Research – GI Oncology and Co-Leader of the Molecular Tumor Board. He received his MD from the University of Chicago - Pritzker School of Medicine. He completed his fellowship training in Hematology and Medical Oncology at Duke University. Dr. Strickler’s clinic specializes on the treatment of gastrointestinal malignancies, with a particular emphasis on colorectal cancer. His research focuses on precision cancer medicine: identification of genomic biomarkers that predict sensitivity or resistance to targeted therapies and immunotherapy. Nationally, he is a member of the American Society of Clinical Oncology (ASCO) Treatment Guidelines Committee for Advanced Colon Cancer.
  • Tanios Bekaii-Saab, MD, FACP

    Tanios Bekaii-Saab, MD, FACP

    Tanios Bekaii-Saab, MD, FACP

    Professor of Medicine

    Tanios Bekaii-Saab, MD, is a Professor of Medicine at the Mayo Clinic College of Medicine and Science and the Leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center. He is also the Medical Director of the Cancer Clinical Research Office and Chair for Medical Oncology for the Division of Hematology/Oncology at the Mayo Clinic in Phoenix, Arizona. In addition, Dr. Bekaii-Saab is the consortium chair for the ACCRU research Network. Also, he is the co-leader of the Hepatobiliary Cancer Committee of the Alliance for Clinical Trials in Oncology cooperative group as well as the co-chair of the National Cancer Institute’s Hepatobiliary Task Force. Furthermore, Dr. Bekaii-Saab has authored or co-authored more than 500 peer reviewed publications, abstracts, and book chapters.

CME Information

Global Logo PQH Logo
A New Path for HER2-positive Metastatic Colorectal Cancer
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.


This activity is supported by an educational grant from Seagen Inc.


This activity was released on February 8, 2023 and is valid until February 8, 2024. Requests for credit must be made no later than February 8, 2024


Oncologists - medical, surgical, radiation; gastroenterologists, in addition to oncology nurses; NP/PA in oncology settings; oncology pharmacists


Novel investigational targeted therapies have shown encouraging results in patients with HER2+ metastatic colorectal cancer (mCRC). To ensure these therapies are used effectively, it is important to test for tumor HER2 status and recognize where HER2-directed treatment modalities fit into the current paradigm.

Join a panel of expert gastrointestinal oncologists to discuss selection of the most appropriate therapy based on tumor biomarker status, minimization of adverse events, and strategies to improve patient quality of life. Panelists will review practice-changing data on the efficacy and safety of new and emerging therapies, with a focus on HER2-directed therapies in the advanced setting and determining which treatments are appropriate for which patients.


After completing this activity, the participant should be better able to:
  • Discuss HER2 testing and its significance for selecting therapy in the management of patients with mCRC
  • Evaluate efficacy data from practice-changing clinical trials on new and emerging HER2-directed therapies for previously treated mCRC
  • Outline adverse events associated with HER2-directed therapies and approaches to mitigate these effects


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Tanios Bekaii-Saab, MD
Professor , Medical Oncology
Mayo Clinic College of Medicine and Science
Consulting Fee: Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGA, Merck, Stemline, AbbVie, Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, AstraZeneca, Deciphera, Zai Labs, Aptitude Health, Illumina, Foundation Medicine, Sanofi, Imugene, Immuneering, Xilis, Replimune, Artiva, Sun Biopharma
Contracted Research: Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, BMS
Other: Patents with Imugene and Recursion
John Strickler, MD
Associate Professor
Associate Director of Clinical Research – GI Oncology
Co-Leader of the Molecular Tumor Board.
Duke University
Consulting Fee: Abbvie, Amgen, AstraZeneca, Bayer, Beigene, Eli Lilly, GSK, Natera, Pfizer, Pionyr Immunotherapeutics, Seagen, Silverback Therapeutics, Takeda, Viatris
Contracted Research: Abbvie, Amgen, AStar D3, Bayer, Curegenix, Daiichi-Sankyo, Eli Lilly, Erasca, Gossamer Bio, Leap Therapeutics, Nektar, Roche/ Genentech, Sanofi, Seagen, Silverback Therapeutics

The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at